|
|
 |
|
NIH-SPONSORED RESEARCH NETWORKS
IN MATERNAL-FETAL MEDICINE
• Designed to investigate the safety and
efficacy of treatment and management strategies
to care
for critically ill children, as well as the
pathophysiological bases of critical illness and injury in childhood.
• This collaborative clinical research network
is accelerating pediatric critical care research
and leading to the evaluation of promising
new approaches to life support and critical decision-making
in complex illnesses.
• PI at WSU is Dr. Kathleen Meert.
• Conducts multi-center clinical trials
and observational studies in neonatal medicine.
• The collaborative nature of the NRN also provides
access to a multi-cultural, multi-ethnic,
and socio-demographically varied population in which
widespread substance abuse was demonstrated.
• PI at WSU is Dr. Seetha Shankaran, Division Chief,
Neonatology.
• The Maternal Lifestyle Study (MLS) is an active
study of the NICHD Multi-center Neonatal Research
Network. The objective of MLS is to evaluate
the relationship between maternal use of cocaine
during pregnancy and the incidence and prevalence
of acute neonatal complications and long term
neurodevelopmental outcome of both premature
and full term infants. . MLS has also received
funds from NIDA, ACYF, and CSAT.
• MLS began in
1993 at four NRN centers. During a two year
enrollment, 16,000 infants were
evaluated for Phase I of the study. 1,388
children are enrolled in the follow-up phase,
599 are
seen in the Wayne State University MLS clinic
located in the Clinical Research Center of
Michigan. The follow-up cohort is a group
match with equal numbers of exposed and non-exposed
children. The children are evaluated annually
with neurobehavorial assessments and research
interviews. The caretakers of the children
also participate in research interviews.
• The Maternal
Lifestyle Study has produced numerous publications
and presentations.
• Dr. Seetha Shankaran is the
Principal Investigator for Wayne State University.
The Research Coordinators
are Eunice Woldt, MSN and Jay Ann Nelson, BSN.
• The mission of the PPRU Network is
to develop novel drug therapies, perform appropriate
clinical drug trials and facilitate and promote
pediatric labeling of new drugs and drugs already
on the market.
•
The overall approach to testing pharmaceuticals
for children, a large patient population, high-quality
clinical research, and expertise in pediatric
drug studies make the PPRU Network an ideal
investigative site for pharmaceutical companies
seeking to market drugs with indications for
newborns and children.
•
PI at WSU is Dr. Jacob Aranda, Director of
Child Pharmacology. Co-PI is Dr. Mary Lieh
Lai, Director, ICU and Critical Care Medicine
Fellowship.
• The (RMN) was established in 1990
to carry out large, multicenter clinical trials
in the areas
of male and female infertility, reproductive
diseases and disorders.
• Investigators are currently conducting a study
examining pregnancy outcome in women with
polycystic ovarian syndrome who have been randomized to
receive clomiphene citrate, metformin,
or both, for ovulation induction.
• PI at WSU is Dr. Michael Diamond, Director of
the WSU Division of Reproductive Endocrinology
and Infertility.
• The National Institute of Child Health
and Human Development (NICHD) created the Maternal
Fetal
Medicine Units (MFMU) Network in 1986 to
focus on clinical questions in maternal fetal
medicine
and obstetrics, particularly with respect
to the continuing problem of preterm birth.
• Operating under cooperative agreements, the current
Network is comprised of fourteen university-based
clinical centers and a data coordinating
center. More than 30 randomized clinical trials, cohort
studies and registries have been completed
or are in progress.
• PI at WSU is Dr. Yoram Sorokin, Director of Maternal
Fetal Medicine.
• The goal of this network is to conduct
meaningful and rigorous multi-institutional
research into
the prevention and management of acute
illnesses and injuries in children and youth
across the
continuum of emergency medicine health
care.
• The PECARN network consists of a coordinating
data center, four research node centers
(RNCs), and over 20 Hospital Emergency
Department Affiliates
(HEDAs) that represent academic, community,
urban, rural, general, and children's hospitals. The
entire network serves approximately 800,000
acutely ill and injured children every year.
• PI at WSU is Dr. Prashant Mahajan, Research Director
and Associate Fellowship Director, Pediatric
Emergency Medicine.
Primary Vesicoureteral Reflux in Children
• Vesicoureteral reflux (VUR) is a common
congenital abnormality in young children and
is often associated
with recurrent urinary tract infection. It
is believed that in such patients an abnormal
flow
of infected urine from the bladder into the
kidneys causes significant damage in the kidneys,
which
in severe cases may cause kidney failure.
To prevent renal damage, patients with VUR
are currently
treated with daily antibiotics for years,
until the resolution of the VUR. Depending
on the severity
and the clinical course of the VUR some patients
require surgical correction. The main concerns
with prolonged antibiotic treatment include
antibiotic resistance, need for repeated radiology
tests
to monitor the resolution of VUR, and regular
hospital visits. Recent research has raised
some doubts about the current medical or surgical
management practices for the management of
VUR.
The main objective of the study is to examine
if long-term antibiotics are necessary in
such children.
•
To answer this and other related questions, the
NIDDK (NIH) has funded Dr. Tej Mattoo, Chief
of Pediatric Nephrology at Children’s Hospital
of MI and four other investigators across the
country (Johns Hopkins, Children’s Hospital
of Philadelphia, Children’s Hospital of
Pittsburg, and Women and Children’s
Hospital of Buffalo) for a 5-year study that
will include
600 children with VUR.
|
|
CRCM
Home
